A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis.

Ashutosh D. Wechalekar, Stefan O. Schonland, Efstathios Kastritis, Julian D. Gillmore, Meletios A. Dimopoulos, Thirusha Lane, Andrea Foli, Darren Foard, Paolo Milani, Lisa Rannigan, Ute Hegenbart, Philip N. Hawkins, Giampaolo Merlini, Giovanni Palladini

Research output: Contribution to journalArticle

Abstract

Treatment outcomes of patients with cardiac stage III light chain (AL) amyloidosis remain poorly studied. Such cases have been excluded from most clinical studies due to perceived dismal prognosis. We report treatment outcomes of 346 patients with stage III AL amyloidosis from the United Kingdom, Italy, Germany, and Greece. Median overall survival (OS) was 7 months with OS at 3, 6, 12, and 24 months of 73%, 55%, 46%, and 29%, respectively; 42% died before first response evaluation. On an intention-to-treat basis, the overall hematologic response rate was 33%, including a complete response rate of 12%. OS rates at 12 and 24 months, respectively, for 201 response evaluable patients were 88% and 85% for complete responders, 74% and 53% for partial responders, and 39% and 22% for nonresponders. Forty-five percent of responders achieved an organ response. Amino-terminal fragment of brain-type natriuretic peptide (NT-proBNP) >8500 ng/L and systolic blood pressure (SBP)

Original languageEnglish
Pages (from-to)3420-3427
Number of pages8
JournalBlood
Volume121
Issue number17
DOIs
Publication statusPublished - Apr 25 2013

Fingerprint

Brain Natriuretic Peptide
Blood pressure
Amyloidosis
Blood Pressure
Survival
Greece
Italy
Germany
Survival Rate
Light
pro-brain natriuretic peptide (1-76)

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Wechalekar, A. D., Schonland, S. O., Kastritis, E., Gillmore, J. D., Dimopoulos, M. A., Lane, T., ... Palladini, G. (2013). A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood, 121(17), 3420-3427. https://doi.org/10.1182/blood-2012-12-473066

A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. / Wechalekar, Ashutosh D.; Schonland, Stefan O.; Kastritis, Efstathios; Gillmore, Julian D.; Dimopoulos, Meletios A.; Lane, Thirusha; Foli, Andrea; Foard, Darren; Milani, Paolo; Rannigan, Lisa; Hegenbart, Ute; Hawkins, Philip N.; Merlini, Giampaolo; Palladini, Giovanni.

In: Blood, Vol. 121, No. 17, 25.04.2013, p. 3420-3427.

Research output: Contribution to journalArticle

Wechalekar, AD, Schonland, SO, Kastritis, E, Gillmore, JD, Dimopoulos, MA, Lane, T, Foli, A, Foard, D, Milani, P, Rannigan, L, Hegenbart, U, Hawkins, PN, Merlini, G & Palladini, G 2013, 'A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis.', Blood, vol. 121, no. 17, pp. 3420-3427. https://doi.org/10.1182/blood-2012-12-473066
Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013 Apr 25;121(17):3420-3427. https://doi.org/10.1182/blood-2012-12-473066
Wechalekar, Ashutosh D. ; Schonland, Stefan O. ; Kastritis, Efstathios ; Gillmore, Julian D. ; Dimopoulos, Meletios A. ; Lane, Thirusha ; Foli, Andrea ; Foard, Darren ; Milani, Paolo ; Rannigan, Lisa ; Hegenbart, Ute ; Hawkins, Philip N. ; Merlini, Giampaolo ; Palladini, Giovanni. / A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. In: Blood. 2013 ; Vol. 121, No. 17. pp. 3420-3427.
@article{1ff651bb772245ed810f545e889d0d32,
title = "A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis.",
abstract = "Treatment outcomes of patients with cardiac stage III light chain (AL) amyloidosis remain poorly studied. Such cases have been excluded from most clinical studies due to perceived dismal prognosis. We report treatment outcomes of 346 patients with stage III AL amyloidosis from the United Kingdom, Italy, Germany, and Greece. Median overall survival (OS) was 7 months with OS at 3, 6, 12, and 24 months of 73{\%}, 55{\%}, 46{\%}, and 29{\%}, respectively; 42{\%} died before first response evaluation. On an intention-to-treat basis, the overall hematologic response rate was 33{\%}, including a complete response rate of 12{\%}. OS rates at 12 and 24 months, respectively, for 201 response evaluable patients were 88{\%} and 85{\%} for complete responders, 74{\%} and 53{\%} for partial responders, and 39{\%} and 22{\%} for nonresponders. Forty-five percent of responders achieved an organ response. Amino-terminal fragment of brain-type natriuretic peptide (NT-proBNP) >8500 ng/L and systolic blood pressure (SBP)",
author = "Wechalekar, {Ashutosh D.} and Schonland, {Stefan O.} and Efstathios Kastritis and Gillmore, {Julian D.} and Dimopoulos, {Meletios A.} and Thirusha Lane and Andrea Foli and Darren Foard and Paolo Milani and Lisa Rannigan and Ute Hegenbart and Hawkins, {Philip N.} and Giampaolo Merlini and Giovanni Palladini",
year = "2013",
month = "4",
day = "25",
doi = "10.1182/blood-2012-12-473066",
language = "English",
volume = "121",
pages = "3420--3427",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "17",

}

TY - JOUR

T1 - A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis.

AU - Wechalekar, Ashutosh D.

AU - Schonland, Stefan O.

AU - Kastritis, Efstathios

AU - Gillmore, Julian D.

AU - Dimopoulos, Meletios A.

AU - Lane, Thirusha

AU - Foli, Andrea

AU - Foard, Darren

AU - Milani, Paolo

AU - Rannigan, Lisa

AU - Hegenbart, Ute

AU - Hawkins, Philip N.

AU - Merlini, Giampaolo

AU - Palladini, Giovanni

PY - 2013/4/25

Y1 - 2013/4/25

N2 - Treatment outcomes of patients with cardiac stage III light chain (AL) amyloidosis remain poorly studied. Such cases have been excluded from most clinical studies due to perceived dismal prognosis. We report treatment outcomes of 346 patients with stage III AL amyloidosis from the United Kingdom, Italy, Germany, and Greece. Median overall survival (OS) was 7 months with OS at 3, 6, 12, and 24 months of 73%, 55%, 46%, and 29%, respectively; 42% died before first response evaluation. On an intention-to-treat basis, the overall hematologic response rate was 33%, including a complete response rate of 12%. OS rates at 12 and 24 months, respectively, for 201 response evaluable patients were 88% and 85% for complete responders, 74% and 53% for partial responders, and 39% and 22% for nonresponders. Forty-five percent of responders achieved an organ response. Amino-terminal fragment of brain-type natriuretic peptide (NT-proBNP) >8500 ng/L and systolic blood pressure (SBP)

AB - Treatment outcomes of patients with cardiac stage III light chain (AL) amyloidosis remain poorly studied. Such cases have been excluded from most clinical studies due to perceived dismal prognosis. We report treatment outcomes of 346 patients with stage III AL amyloidosis from the United Kingdom, Italy, Germany, and Greece. Median overall survival (OS) was 7 months with OS at 3, 6, 12, and 24 months of 73%, 55%, 46%, and 29%, respectively; 42% died before first response evaluation. On an intention-to-treat basis, the overall hematologic response rate was 33%, including a complete response rate of 12%. OS rates at 12 and 24 months, respectively, for 201 response evaluable patients were 88% and 85% for complete responders, 74% and 53% for partial responders, and 39% and 22% for nonresponders. Forty-five percent of responders achieved an organ response. Amino-terminal fragment of brain-type natriuretic peptide (NT-proBNP) >8500 ng/L and systolic blood pressure (SBP)

UR - http://www.scopus.com/inward/record.url?scp=84879458198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879458198&partnerID=8YFLogxK

U2 - 10.1182/blood-2012-12-473066

DO - 10.1182/blood-2012-12-473066

M3 - Article

C2 - 23479568

AN - SCOPUS:84879458198

VL - 121

SP - 3420

EP - 3427

JO - Blood

JF - Blood

SN - 0006-4971

IS - 17

ER -